Selected article for: "care point and early discharge"
Author: Stauning, Marius Ahm; Altintas, Izzet; Kallemose, Thomas; Eugen-Olsen, Jesper; Lindstrøm, Mette Bendtz; Rasmussen, Line Jee Hartmann; Gamst-Jensen, Hejdi; Nehlin, Jan O; Andersen, Ove; Tingleff, Jens
Title: Soluble urokinase plasminogen activator receptor as a decision marker for early discharge of patients with COVID-19 symptoms in the emergency department
  • Cord-id: m88vln41
  • Document date: 2021_3_26
    • ID: m88vln41
    Snippet: BACKGROUND: SARS-CoV-2 strains healthcare capacity. Better risk stratification, with discharge of patients with a predicted mild disease trajectory can ease this burden. Elevated blood soluble urokinase plasminogen activator receptor (suPAR) has previously been shown associated with risk of intubation in confirmed COVID-19 patients. OBJECTIVE: To evaluate if point-of-care measures of suPAR in patients presenting at the emergency department (ED) with symptoms of COVID-19 can identify patients tha
    Document: BACKGROUND: SARS-CoV-2 strains healthcare capacity. Better risk stratification, with discharge of patients with a predicted mild disease trajectory can ease this burden. Elevated blood soluble urokinase plasminogen activator receptor (suPAR) has previously been shown associated with risk of intubation in confirmed COVID-19 patients. OBJECTIVE: To evaluate if point-of-care measures of suPAR in patients presenting at the emergency department (ED) with symptoms of COVID-19 can identify patients that can be safely discharged. METHODS: Observational cohort study including all patients in the ED with symptoms of COVID-19 from March 19(th) to April 3(rd), 2020. Soluble urokinase plasminogen activator receptor was measured at first presentation. Review of electronic patient records 14 days after admission were used to assess disease trajectory. Primary endpoints were mild, moderate, severe, or very severe trajectory. The predictive value of suPAR, National early warning score (NEWS), C-reactive protein (CRP), and duration of symptoms (DOS) was calculated using receiver operating characteristics (ROC). RESULTS: Of 386 patients, 171 (44%) patients had a mild disease trajectory, 79 (20%) a moderate, 63 (16%) a severe, and 73 (19%) a very severe disease trajectory. Low suPAR was a strong marker of mild disease trajectory. Results suggest a cut-off for discharge for suPAR<2.0 ng/ml if suPAR is used as a single parameter, and 3.0 ng/ml when combined with NEWS=<4 and CRP<10 mg/l- CONCLUSION: suPAR is a potential biomarker for triage and safe early discharge of patients with COVID-19 symptoms in the ED. suPAR can be used even before SARS-CoV-2 status is known.

    Search related documents:
    Co phrase search for related documents
    • acute heart failure and liver failure: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute heart failure and logistic regression model: 1, 2
    • acute illness and admission prior: 1, 2, 3, 4, 5, 6
    • acute illness and liver failure: 1, 2, 3, 4
    • acute illness and logistic regression model: 1, 2, 3, 4, 5
    • acute illness and low clinical risk: 1
    • acute illness severity and admission prior: 1
    • acute illness severity and liver failure: 1
    • acute liver failure and admission prior: 1
    • acute liver failure and liver failure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute lung failure and liver failure: 1, 2, 3
    • acute organ failure and admission blood sample: 1
    • acute organ failure and admission prior: 1
    • acute organ failure and liver failure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • admission measure and logistic regression model: 1
    • admission prior and liver failure: 1, 2, 3
    • admission prior and logistic regression model: 1, 2, 3, 4, 5
    • liver failure and logistic regression model: 1, 2, 3
    • logistic regression model and low clinical risk: 1